Three independent discounted-cash-flow-style models value Heron Therapeutics, Inc. every trading day. 1 of 3 currently price HRTX above its market price.
| Free Cash Flow model | $-41.15 |
| Excess Profit model | $-41.34 |
| Residual Earnings model | $11,111.66 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | -12.6% |
| Net debt / EBITDA | — |
| Gross margin | +73.3% |
| Revenue CAGR | +12.9% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -9.4% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open HRTX in StockKitty